Diagnosis of Parkinson's Disease via the Metabolic Fingerprint in Saliva by Deep Learning.

Journal: Small methods
PMID:

Abstract

Parkinson's disease (PD) is the second cause of the neurodegenerative disorder, affecting over 6 million people worldwide. The World Health Organization estimated that population aging will cause global PD prevalence to double in the coming 30 years. Optimal management of PD shall start at diagnosis and requires both a timely and accurate method. Conventional PD diagnosis needs observations and clinical signs assessment, which are time-consuming and low-throughput. A lack of body fluid diagnostic biomarkers for PD has been a significant challenge, although substantial progress has been made in genetic and imaging marker development. Herein, a platform that noninvasively collects saliva metabolic fingerprinting (SMF) by nanoparticle-enhanced laser desorption-ionization mass spectrometry with high-reproducibility and high-throughput, using ultra-small sample volume (down to 10 nL), is developed. Further, excellent diagnostic performance is achieved with an area-under-the-curve of 0.8496 (95% CI: 0.7393-0.8625) by constructing deep learning model from 312 participants. In conclusion, an alternative solution is provided for the molecular diagnostics of PD with SMF and metabolic biomarker screening for therapeutic intervention.

Authors

  • Wei Xu
    College of Food and Bioengineering, Henan University of Science and Technology, Luoyang, 471023 China.
  • Lina Chen
    Department of Ophthalmology, The Third People's Hospital of Dalian, Dalian, Liaoning Province, China.
  • Guoen Cai
    Department of Neurology, Fujian Medical University Union Hospital, Fujian Key Laboratory of Molecular Neurology and Institute of Neuroscience, Fujian Medical University, Fuzhou, 350001, P. R. China.
  • Ming Gao
    State Key Laboratory of Environmental Chemistry and Ecotoxicology, Research Center for Eco-Environmental Sciences, Chinese Academy of Sciences, Beijing 100085, China.
  • Yifan Chen
    Adam Smith Business School, University of Glasgow, Scotland, United Kingdom.
  • Jun Pu
    Center for the Science of Therapeutics, Broad Institute of Harvard and MIT , 7 Cambridge Center, Cambridge, Massachusetts 02142, United States.
  • Xiaochun Chen
    Department of Psychiatry, Boston University School of Medicine, Boston, MA 02118, USA.
  • Ning Liu
    School of Public Health, Hangzhou Normal University, Hangzhou, China.
  • Qinyong Ye
    Department of Neurology, Fujian Medical University Union Hospital, Fujian Key Laboratory of Molecular Neurology and Institute of Neuroscience, Fujian Medical University, Fuzhou, 350001, P. R. China.
  • Kun Qian
    Key Laboratory of Brain Health Intelligent Evaluation and Intervention (Beijing Institute of Technology), Ministry of Education, Beijing, China.